Wikipedia

Nisa Leung

Nisa Leung (Chinese:梁颕宇 or 梁颖宇) is a venture capitalist and managing partner at Qiming Venture Partners. She has been named on the Forbes Midas List for five consecutive years in 2019, 2020, 2021,2022 and 2023.[1][2][3][4][5] and Best Women Venture Capitalists by Forbes China for three years.[6][7][8] Nisa was also named one of the Most Powerful Women in Business in China by Fortune China in 2022 and 2023.[9] Nisa is widely known as China's leading investor in healthcare.[10][11][12][13]

Education edit

Nisa earned a Bachelor of Science degree from Cornell University and graduated from Stanford Graduate School of Business in 2001 with an MBA.

Career edit

Nisa started her career in healthcare investment after realizing there was a lack of advanced therapeutics in China when her family was seeking treatments for her distant uncle, who was diagnosed with liver cancer.[14][15]

Prior to joining Qiming Venture Partners in 2006, she co-founded Biomedic Holdings, which had operations and investments in medical devices, pharmaceuticals, and health care services in China including Novamed Pharmaceuticals (acquired by SciClone NASDAQ:SCLN) and U-Systems (acquired by GE Healthcare). She was also Venture Partner of PacRim Ventures in Menlo Park and was previously with Softbank/Mobius Venture Capital.[16]

Leading Qiming's healthcare investments, Nisa has backed nearly 200 healthcare companies.[17] She currently sits on the board of Zai Lab (NASDAQ:ZLAB; HKSE:9688), CanSino Biologics(SSE:688185; HKSE:6185), Caidya, Chain Medical Labs, Belief BioMed, Zencore Biologics, Valgen MedTech, Alamar Biosciences among others. Her other investments include Gan&Lee (SSE:603087), New Horizon Health (HKSE:6606), Berry Genomics (SZSE:000710), CITIC Pharma (acquired by Shanghai Pharmaceutical HKSE: 2607), Crown Bioscience (acquired by JSR Life Sciences), Aeonmed Medical, Novast Pharmaceuticals, Nurotron, Origene Technologies (acquired by VCAN Bio SSE:600645), Richen, Vision Pro, MEDx, Cure Genetics, Goodwill (SSE:688246), SinoCellTech (SSE:688520), Sino Biological (SZSE:301047), Apollomics (NASDAQ:APLM), SinoUnited Health, Schrödinger (NASDAQ:SDGR), Recursion (NASDAQ:RXRX), Insilico Medicine, Structure Therapeutics (NASDAQ:GPCR), Jacobio (HKSE:1167), Hope Medicine, Sinotau, PlusLife among others.[18]

Nisa is recognized as playing a key role in China's biotech boom and innovation.[19][20]

She serves as Independent Non-executive Director of the Hong Kong Exchanges and Clearing Limited.[21] She is also a visiting lecturer at Harvard Law School,[22] member of Stanford Graduate School of Business Advisory Council,[23] Council Member of China Pharmaceutical Innovation and Research Development Association (PhIRDA), Founding Member and Chair of Pharmaceutical Innovation Investment Specialty Committee of PhIRDA. [24]

References edit

  1. ^ "No. 54 Nisa Leung". Forbes. Retrieved 2023-04-19.
  2. ^ Flannery, Russell. "Mom's Encouragement Lands China Healthcare Investor On 2020 Forbes Midas List". Forbes. Retrieved 2023-04-19.
  3. ^ Standard, The. "Qiming's Duane Kuang, Nisa Leung named on 2021 Forbes Midas List". The Standard. Retrieved 2023-04-19.
  4. ^ "Nisa Leung". Forbes. Retrieved 2023-04-19.
  5. ^ "The Midas List 2023". Forbes. Retrieved 2023-05-06.
  6. ^ Forbes China (2023-01-16). "福布斯中国2023女性创投人20揭晓：用敏锐、坚韧应对不确定性". Forbes China 福布斯中国.
  7. ^ Forbes China (2022-03-24). "福布斯中国发布2022年中国女性创投人20". Forbes China 福布斯中国.
  8. ^ Forbes China (2023-04-19). "2018福布斯中国最佳女性创投人TOP25". Forbes China 福布斯中国.
  9. ^ "梁颕宇". 财富中文网 (in Chinese (China)). Retrieved 2023-04-19.
  10. ^ Wang, Catherine. "How China's Leading Female Healthcare Investor Backs Billion-Dollar Biotech Companies". Forbes. Retrieved 2023-04-19.
  11. ^ Ngui, Yantoultra; Daga, Anshuman; Ngui, Yantoultra (2022-09-27). "'Overinvested' China healthcare sector set for shake up, top venture fund says". Reuters. Retrieved 2023-04-19.
  12. ^ "NISA LEUNG : Pioneering HK investor driven by improving lives and world-changing technologies". www.hkstpnewsroom.com. Retrieved 2023-04-19.
  13. ^ Forbes China (2021-04-15). "连续三年唯一上榜的中国医疗健康投资人，启明创投梁颕宇怎么看投资机会 | 全球最佳创投人榜". Forbes China 福布斯中国.
  14. ^ "Investing in China: It's Still "the Wild, Wild West"". Stanford Graduate School of Business. 31 January 2023. Retrieved 2023-04-19.
  15. ^ Wang, Catherine. "How China's Leading Female Healthcare Investor Backs Billion-Dollar Biotech Companies". Forbes. Retrieved 2023-04-19.
  16. ^ "Nisa Leung | Qiming Venture Partners". www.qimingvc.com. Retrieved 2023-04-19.
  17. ^ "【2023投资风向标】对话启明创投：医疗创新由点向面推进，重点关注跨界融合与效率提升_腾讯新闻". new.qq.com. Retrieved 2023-04-19.
  18. ^ "Nisa Leung | Qiming Venture Partners". www.qimingvc.com. Retrieved 2023-04-19.
  19. ^ Capital, TrueBridge. "The Midas List 2022: Return Of The Top Female Investors". Forbes. Retrieved 2023-04-19.
  20. ^ "创业迷梁颕宇，批量收割医疗投资 | 界面 · 财经号". m.jiemian.com. Retrieved 2023-04-19.
  21. ^ "LEUNG Nisa Bernice Wing-Yu". www.hkexgroup.com. Retrieved 2023-04-19.
  22. ^ "HarvardKey - Harvard University Authentication Service". www.pin1.harvard.edu. Retrieved 2023-04-19.
  23. ^ "Advisory Council Members". Stanford Graduate School of Business. Retrieved 2023-04-19.
  24. ^ "专委会". www.phirda.com. Retrieved 2023-04-19.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Nisa_Leung&oldid=1203545502"